Carboplatin

Absorption

The Cmax and AUC of carboplatin increase proportionally with increasing doses. A 75 mg/m2 dose reaches a Cmax of 9.06 ± 0.74 μg/mL, with an AUC of 27.18 ± 11.28 h*μg/mL. A 450 mg/m2 dose reaches a Cmax of 55.39 ± 18.30 μg/mL, with an AUC of 224.41 ± 69.07 h*μg/mL.

Toxicity

Patients experiencing an overdose of carboplatin may present with pronounced neutropenia and hepatotoxicity. Treat patients with symptomatic and supportive measures, which may include delaying their next treatment.

Description

Carboplatin is a second generation, platinum-containing antineoplastic agent with significantly reduced nephro-, neuro-, and ototoxicity in comparison to cisplatin. It is effective in the treatment of advanced ovarian carcinoma of epithelial origin and small cell carcinoma of the lung.

Description

Carboplatin, an alkylating agent used to treat ovarian and lung cancers, interferes with the growth of cancer cells by inhibiting DNA synthesis. Carboplatin is less toxic than its predecessor cisplatin, but it can interfere with the growth of healthy cells, including blood cells. Carboplatin''s mechanism of action is not well understood.

The Uses of Carboplatin

Data on carboplatin production have not been found. Carboplatin is used in chemotherapy to treat cancer, and more particularly to treat cancer of ovary, embryonal carcinoma of the testis, microcellular carcinoma of the lung, neuroblastoma, and squamous cell carcinomas of the head and neck.

What are the applications of Application

Carboplatin is an antitumor agent that binds to DNA leading to apoptosis

Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.

Indications

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Pharmacokinetics

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Carboplatin has a long duration of action as it is given every 4 weeks, and a narrow therapeutic index. Patients should be counselled regarding bone marrow suppression and anemia.

Metabolism

Carboplatin is predominantly eliminated as the unchanged parent compound.